[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].

Autor: Boyko AN; Pirogov National Medical Research University, Moscow, Russia.; Federal Center for Brain Research and Neurotechnologies, Moscow, Russia., Bakhtiyarova KZ; Kuvatov Republican Clinical Hospital, Ufa, Russia., Boyko OV; Federal Center for Brain Research and Neurotechnologies, Moscow, Russia., Dudin VA; Center for Cardiology and Neurology, Kirov, Russia., Zaslavskii LG; Leningrad Regional Clinical Hospital, St. Petersburg, Russia., Malkova NA; Regional Clinical Hospital, Novosibirsk, Russia., Parshina EV; Semashko Regional Clinical Hospital, Nizhny Novgorod, Russia., Poverennova IY; Seredavin Regional Clinical Hospital, Samara, Russia., Sivertseva SA; Medical and Sanitary Unit «Neftyanik», Tyumen, Russia., Totolyan NA; Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia., Shchur SG; Filatov Moscow City Clinical Hospital No. 15, Moscow, Russia., Khabirov FA; Republican Clinical Neurological Center, Kazan, Russia., Goncharova ZA; Rostov State Medical University, Rostov-on-Don, Russia., Zakharova MN; Research Center of Neurology, Moscow, Russia., Bolsun DD; JSC «BIOCAD», St. Petersburg, Russia., Zinkina-Orikhan AV; JSC «BIOCAD», St. Petersburg, Russia., Lin'kova YN; JSC «BIOCAD», St. Petersburg, Russia., Chernovskaya TV; JSC «BIOCAD», St. Petersburg, Russia., Porozova AA; JSC «BIOCAD», St. Petersburg, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2023; Vol. 123 (2), pp. 52-59.